Continue 7.5 mg Mirtazapine for Now, But Monitor Closely for Response
If 7.5 mg mirtazapine is providing adequate relief of your insomnia and anxiety symptoms, continue at this dose rather than increasing immediately. However, if symptoms persist after 1-2 weeks, dose escalation to 15 mg may be warranted.
Rationale for Starting Low
The evidence strongly supports starting with the lowest effective dose of mirtazapine for insomnia:
7.5 mg is highly effective for insomnia. A 2025 randomized controlled trial in older adults showed that 7.5 mg mirtazapine significantly reduced insomnia severity (mean ISI score improvement of -6.5 points vs -2.9 for placebo, p=0.003) 1. This same dose improved total sleep time and sleep efficiency.
Lower doses may actually work better. A retrospective study found that the minimum dosage of 7.5 mg corresponded to the highest percentage of responders (52.5%), and patients on lower doses (7.5-15 mg) had significantly better response rates (100%) compared to those on higher doses (15-30 mg, only 53.84% response rate, p<0.001) 2.
The sedating effect is paradoxically stronger at lower doses. At 7.5 mg, mirtazapine's antihistamine (H1) blocking effects predominate, providing sedation. At higher doses (15-45 mg), increased noradrenergic activity may counteract some sedative effects 3.
When to Consider Dose Increase
Increase to 15 mg if:
- Insomnia symptoms remain moderate-to-severe after 1-2 weeks at 7.5 mg
- Anxiety symptoms are prominent and not adequately controlled
- You're treating comorbid depression (antidepressant effects require 15-45 mg) 4
The FDA-approved dosing for depression starts at 15 mg, with increases up to 45 mg 4. However, for insomnia specifically, guidelines note that mirtazapine is used "in lower than antidepressant therapeutic dosages" and its efficacy for insomnia "is not well established" by FDA standards 5.
Important Monitoring Points
Watch for these side effects at any dose:
- Daytime sedation/hangover effects - Both 7.5 mg and 50 mg quetiapine caused measurable next-day sleepiness and reduced sustained attention in controlled trials 6
- Increased appetite and weight gain - Common at all doses 3, 7
- Orthostatic hypotension - Particularly in elderly or those with cardiovascular disease 4
Serious but rare concerns:
- Low white blood cell count (fever, sore throat, infections)
- Serotonin syndrome if combined with other serotonergic drugs
- Hyponatremia, especially in elderly 4
Dosing Timeline
If increasing dose:
- Wait 1-2 weeks between dose changes to properly assess response 4
- Typical escalation: 7.5 mg → 15 mg → 30 mg → maximum 45 mg
- Take once daily, preferably in the evening before sleep 4
Anxiety-Specific Considerations
For anxiety symptoms, mirtazapine shows particular benefit in patients with severe generalized anxiety. A secondary analysis found that patients with severe anxiety (GAD-7 ≥16) had significantly greater benefit from mirtazapine augmentation compared to those with mild/no anxiety 8. A 2026 meta-analysis confirmed mirtazapine's effectiveness for anxiety in depression and as SSRI augmentation in PTSD 9.
Critical Caveats
- Not FDA-approved for insomnia - Mirtazapine is used off-label for this indication 5
- Avoid abrupt discontinuation - Taper gradually to prevent withdrawal symptoms (dizziness, sensory disturbances, agitation, nausea) 4
- Avoid alcohol and benzodiazepines during treatment due to additive sedation 4
- Screen for bipolar disorder before starting, as mirtazapine can trigger manic episodes 4
Alternative Approach
If 7.5 mg proves insufficient and you want to avoid dose escalation, consider:
- Adding cognitive behavioral therapy for insomnia (CBT-I), which is recommended as first-line treatment 5
- Switching to FDA-approved insomnia medications (zolpidem, eszopiclone, doxepin 3-6 mg) if mirtazapine fails 10
The 2017 AASM guidelines suggest against using trazodone for insomnia but do not specifically address mirtazapine 10. However, the 2008 guidelines position sedating antidepressants like mirtazapine as third-line options after benzodiazepine receptor agonists fail 5.